Evidence map›Paper›PMID 38445818›Full record

ArticleAlzheimer's & dementia : the journal of the Alzheimer's Association2024

Nanoscale imaging of pT217-tau in aged rhesus macaque entorhinal and dorsolateral prefrontal cortex: Evidence of interneuronal trafficking and early-stage neurodegeneration.

Dibyadeep Datta, Isabella Perone, Denethi Wijegunawardana, Feng Liang, Yury M Morozov, Jon Arellano, Alvaro Duque, Zhongcong Xie, Christopher H van Dyck, Mary Kate P Joyce and 1 more

Open access · hybridAbstract read
In one paragraph

Article in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
6.9field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 21 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. APOE ɛ4 carriership determines a faster plasma p-tau217 progression in Aβ-positive individuals.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025
    Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Dibyadeep DattaDepartment of Neuroscience, Yale University, School of Medicine, New Haven, Connecticut, USA.ORCID 0000-0002-5415-3067
Isabella PeroneDepartment of Neuroscience, Yale University, School of Medicine, New Haven, Connecticut, USA.
Denethi WijegunawardanaDepartment of Neuroscience, Yale University, School of Medicine, New Haven, Connecticut, USA.
Feng LiangDepartment of Anesthesia, Critical Care and Pain Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.
Yury M MorozovDepartment of Neuroscience, Yale University, School of Medicine, New Haven, Connecticut, USA.
Jon ArellanoDepartment of Neuroscience, Yale University, School of Medicine, New Haven, Connecticut, USA.
Alvaro DuqueDepartment of Neuroscience, Yale University, School of Medicine, New Haven, Connecticut, USA.
Zhongcong XieDepartment of Anesthesia, Critical Care and Pain Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.
Christopher H van DyckDepartment of Psychiatry, Yale University, School of Medicine, New Haven, Connecticut, USA.
Mary Kate P JoyceDepartment of Neuroscience, Yale University, School of Medicine, New Haven, Connecticut, USA.
Amy F T ArnstenDepartment of Neuroscience, Yale University, School of Medicine, New Haven, Connecticut, USA.
Yale University · USHarvard University · US

Funding

Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9M
Yale Alzheimer Disease Research CenterP30AG066508 · NIA · YALE UNIVERSITY · PI STEPHEN M STRITTMATTER · 2020 to 2026
$30.2M
Institutional Career Development CoreKL2TR001862 · NCATS · YALE UNIVERSITY · PI CANTLEY, LLOYD G, EDELMAN, E. JENNIFER · 2016 to 2025
$12.2M
Pathogenesis of Postoperative Cognitive DysfunctionR01AG041274 · NIA · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI Zhongcong Xie, Guang Yang · 2012 to 2026
$6.7M
NEUROBIOLOGY OF CORTICAL SYSTEMST32NS007224 · NINDS · YALE UNIVERSITY · PI CARDIN, JESSICA A · 1985 to 2025
$4.6M
Yale Macaque Brain ResourceR01MH113257 · NIMH · YALE UNIVERSITY · PI Alvaro Duque · 2017 to 2026
$4.3M
Preclinical assessment of GCPII inhibitors for cognition and tau pathologyR01AG061190 · NIA · YALE UNIVERSITY · PI ARNSTEN, AMY F.T. · 2019 to 2023
$4.2M
General Anesthesia and Alzheimer's Disease NeuropathogenesisRF1AG070761 · NIA · MASSACHUSETTS GENERAL HOSPITAL · PI XIE, ZHONGCONG · 2020 to 2020
$1.9M
Generation and trans-neuronal seeding of phosphorylated T217-Tau in aging macaque cortical circuitsR21AG079145 · NIA · YALE UNIVERSITY · PI DATTA, DIBYADEEP · 2022 to 2022
$461k
NCATS NIH HHS KL2 TR001862NCATS NIH HHS UL1 TR001863NIA NIH HHS P30 AG066508NIA NIH HHS R01 AG041274NIA NIH HHS R01 AG061190NIA NIH HHS R21 AG079145NIA NIH HHS RF1 AG070761NIMH NIH HHS R01 MH113257NINDS NIH HHS T32 NS007224
6 · The paper itself

Abstract

introductionTau phosphorylated at threonine-217 (pT217-tau) is a novel fluid-based biomarker that predicts onset of Alzheimer's disease (AD) symptoms, but little is known about how pT217-tau arises in the brain, as soluble pT217-tau is dephosphorylated post mortem in humans.

methodsWe used multilabel immunofluorescence and immunoelectron microscopy to examine the subcellular localization of early-stage pT217-tau in entorhinal and prefrontal cortices of aged macaques with naturally occurring tau pathology and assayed pT217-tau levels in plasma.

resultspT217-tau was aggregated on microtubules within dendrites exhibiting early signs of degeneration, including autophagic vacuoles. It was also seen trafficking between excitatory neurons within synapses on spines, where it was exposed to the extracellular space, and thus accessible to cerebrospinal fluid (CSF)/blood. Plasma pT217-tau levels increased across the age span and thus can serve as a biomarker in macaques. DISCUSSION: These data help to explain why pT217-tau predicts degeneration in AD and how it gains access to CSF and plasma to serve as a fluid biomarker.

Indexed as

Alzheimer Diseasetau ProteinsAmyloid beta-PeptidesAnimalsBiomarkersDorsolateral Prefrontal CortexMacaca mulattaAmyloid beta-PeptidesBiomarkerstau Proteinsbiomarkerdorsolateral prefrontal cortexentorhinal cortexplasmatau phosphorylated at threonine‐217trafficking

Identifiers

PMID38445818
PMCPMC11032534
OpenAlexW4392518251

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.